(NASDAQ: AMPH) Amphastar Pharmaceuticals's forecast annual revenue growth rate of 3.95% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.34%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.06%.
Amphastar Pharmaceuticals's revenue in 2026 is $745,787,000.On average, 9 Wall Street analysts forecast AMPH's revenue for 2026 to be $33,000,824,593, with the lowest AMPH revenue forecast at $31,169,767,622, and the highest AMPH revenue forecast at $34,349,912,224. On average, 9 Wall Street analysts forecast AMPH's revenue for 2027 to be $34,478,721,729, with the lowest AMPH revenue forecast at $31,186,401,962, and the highest AMPH revenue forecast at $37,538,587,257.
In 2028, AMPH is forecast to generate $35,675,967,692 in revenue, with the lowest revenue forecast at $31,758,793,868 and the highest revenue forecast at $38,458,167,697.